NasdaqCM - Delayed Quote • USD
PDS Biotechnology Corporation (PDSB)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:55 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 1.35M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| BEDU-ADDO FRANK Chief Executive Officer | Conversion of Exercise of derivative security at price 6.57 per share. | Direct | 1,442,345 | Dec 2, 2022 |
| HILL MATTHEW C Chief Financial Officer | Purchase at price 8.90 - 9.00 per share. | Indirect | 27,860 | Dec 13, 2021 |
| BLOOMQUIST DELYLE WADE Former | Purchase at price 9.88 per share. | Direct | 98,778 | Jun 16, 2021 |
| BLOOMQUIST DELYLE WADE Former | Conversion of Exercise of derivative security at price 5.99 per share. | Direct | 17,790 | Jun 16, 2021 |
| FREITAG GREGORY GENE Director | Purchase at price 8.50 per share. | Direct | 49,997 | Jun 15, 2021 |
| VAN VOORHEES SETH L Chief Financial Officer | Purchase at price 8.50 per share. | Direct | 150,000 | Jun 15, 2021 |
| ALI-JACKSON KAMIL Director | Purchase at price 8.50 per share. | Direct | 99,994 | Jun 15, 2021 |
| BEDU-ADDO FRANK Chief Executive Officer | Conversion of Exercise of derivative security at price 6.57 per share. | Direct | 349,353 | Jun 15, 2021 |
| GLOVER STEVE C Director | Purchase at price 8.50 per share. | Direct | 49,997 | Jun 15, 2021 |
| FREITAG GREGORY GENE Director | Stock Award(Grant) at price 1.30 per share. | Direct | 49,920 | Feb 14, 2020 |
| SYKES RICHARD B Director | Stock Award(Grant) at price 1.30 per share. | Direct | 500,000 | Feb 14, 2020 |
| SAIK ANDREW Chief Financial Officer | Stock Award(Grant) at price 1.30 per share. | Direct | 49,920 | Feb 14, 2020 |
| GLOVER STEVE C Director | Stock Award(Grant) at price 1.30 per share. | Direct | 49,920 | Feb 14, 2020 |
| BARER SOL J Director | -- | Indirect | -- | Mar 15, 2019 |
| MIDDLEKAUFF WILLIAM BRADFORD General Counsel | -- | Direct | -- | Mar 15, 2019 |
| LOUGHLIN JAMES J Director | -- | Direct | -- | Mar 15, 2019 |
| CRANE ROSEMARY A Director | -- | Direct | -- | Mar 15, 2019 |
| SPIEGEL ROBERT J Director | -- | Direct | -- | Mar 15, 2019 |
| BLECH ISAAC Director | -- | Direct | -- | Mar 15, 2019 |
| RATCLIFFE LIAM T Director | -- | Direct | -- | Mar 15, 2019 |
| SAIK ANDREW Chief Financial Officer | -- | Direct | -- | Mar 15, 2019 |
| MACDONALD R. LOCH Director | -- | Direct | -- | Mar 15, 2019 |
| LEUTHNER BRIAN A. Chief Executive Officer | -- | Direct | -- | Mar 15, 2019 |
| MACDONALD R. LOCH Officer and Director | Sale at price 16.41 per share. | Direct | 41,025 | Mar 22, 2018 |
| MACDONALD R. LOCH Officer and Director | Sale at price 16.47 - 16.66 per share. | Direct | 165,300 | Mar 21, 2018 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 14.81 - 15.08 per share. | Direct | 74,725 | Mar 2, 2018 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 14.81 - 15.08 per share. | Direct | 74,725 | Mar 2, 2018 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 15.37 - 15.47 per share. | Direct | 77,100 | Feb 23, 2018 |
| MACDONALD R. LOCH Officer and Director | Sale at price 13.75 - 14.49 per share. | Direct | 174,075 | Feb 22, 2018 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 12.96 - 13.14 per share. | Direct | 65,250 | Feb 2, 2018 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 10.11 per share. | Direct | 50,550 | Jan 3, 2018 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 9.68 - 9.97 per share. | Direct | 73,925 | Dec 5, 2017 |
| MARCHIO ALBERT NICHOLAS II Officer | Sale at price 10.00 per share. | Direct | 33,610 | Nov 22, 2017 |
| MARCHIO ALBERT NICHOLAS II Officer | Sale at price 10.00 per share. | Direct | 33,610 | Nov 22, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 10.86 - 10.94 per share. | Direct | 81,800 | Nov 3, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 10.81 - 11.14 per share. | Direct | 82,200 | Oct 4, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 9.94 - 10.37 per share. | Direct | 76,550 | Sep 6, 2017 |
| MARCHIO ALBERT NICHOLAS II Officer | Sale at price 10.42 per share. | Direct | 26,050 | Aug 29, 2017 |
| MARCHIO ALBERT NICHOLAS II Officer | Sale at price 10.39 per share. | Direct | 10,390 | Aug 23, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 10.40 - 10.65 per share. | Direct | 78,950 | Aug 3, 2017 |
| BARER SOL J Director | Conversion of Exercise of derivative security at price 2.39 per share. | Indirect | 29,947 | Jul 7, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 10.08 - 10.27 per share. | Direct | 76,400 | Jul 6, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 11.10 per share. | Direct | 1,110 | Apr 26, 2017 |
| LOUGHLIN JAMES J Director | Purchase at price 9.24 per share. | Indirect | 27,720 | Mar 6, 2017 |
| EINHORN ANDREW J Chief Financial Officer | Conversion of Exercise of derivative security at price 2.39 per share. | Direct | 3,745 | Mar 1, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 9.52 per share. | Direct | 14,280 | Feb 7, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 9.52 - 9.69 per share. | Direct | 28,815 | Feb 6, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 9.38 - 9.61 per share. | Direct | 28,485 | Feb 2, 2017 |
| MACDONALD R. LOCH Officer and Director | Conversion of Exercise of derivative security at price 2.04 per share. | Direct | 51,000 | Jan 23, 2017 |
| LEUTHNER BRIAN A. Chief Executive Officer | Sale at price 11.60 per share. | Direct | 87,000 | Dec 1, 2016 |
Related Tickers
MREO Mereo BioPharma Group plc
2.8100
+1.08%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
XFOR X4 Pharmaceuticals, Inc.
1.1300
-12.40%
EFTR eFFECTOR Therapeutics, Inc.
1.8100
-2.16%
LPTX Leap Therapeutics, Inc.
3.1700
-3.65%
OCUL Ocular Therapeutix, Inc.
4.2000
-9.58%
CLRB Cellectar Biosciences, Inc.
3.0200
-1.31%
MCRB Seres Therapeutics, Inc.
0.7427
+1.81%
ABEO Abeona Therapeutics Inc.
3.1900
+0.63%
MDNAF Medicenna Therapeutics Corp.
1.4000
+0.72%